BetterHelp vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
World's largest online therapy platform, 30,000+ licensed therapists, Sunnyvale CA, owned by Teladoc Health. Consumer-focused text, phone, and video therapy.
About
BetterHelp is a Sunnyvale, California-based online therapy platform founded in 2013 and acquired by Teladoc Health in 2015. The platform is the world's largest online therapy service, with more than 30,000 licensed therapists and counselors available to members across the United States and internationally. BetterHelp is a direct-to-consumer service, allowing individuals to sign up, complete a brief matching questionnaire, and be paired with a therapist within days.\n\nMembers communicate with their therapist through multiple formats including text messaging, live chat, phone calls, and video sessions, offering a level of flexibility and asynchronous access that traditional therapy cannot match. Subscriptions are priced on a weekly or monthly basis with financial assistance available for lower-income members. BetterHelp has heavily invested in consumer brand awareness through podcast advertising and influencer partnerships, making it one of the most recognized names in consumer mental health.\n\nBetterHelp operates as part of Teladoc Health's mental health division alongside Teladoc's other behavioral health offerings, and the parent company's scale provides infrastructure and insurance relationship advantages. Despite facing regulatory scrutiny and advertiser criticism around messaging practices in 2022–2023, BetterHelp remains the dominant player in direct-to-consumer online therapy by volume of active clients and therapist network size.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.